BMS’ Opdivo First EU Approved PD-1 Inhibitor
Bristol-Myers Squibb’s (BMS’) Opdivo for the use in treatment for advanced skin cancer (unresectable or metastatic melanoma in adults) has been the first PD-1 inhibitor to gain approval by the European regulators. Last summer, the inhibitor became the first PD-1 inhibitor to be approved in the world when Japanese regulators approved it. In the US,